Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5160MR)

This product GTTS-WQ5160MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam IL31 gene. The antibody can be applied in Canine atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001165914.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100302725
UniProt ID Q9N0W9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5160MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1816MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ8211MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ15817MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ4066MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ4976MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ8071MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ13834MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ8048MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA H1H3592P3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW